Literature DB >> 19275801

Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions.

W-B Zhou1, M Bai, Y Jin.   

Abstract

OBJECTIVE: To assess the value of vascular endothelial growth factor (VEGF) and endostatin in the differential diagnosis of malignant and tuberculous pleural effusions (PE).
METHODS: Effusion samples were collected from 62 patients with malignant PE caused by lung cancer and from 64 patients with tuberculous pleurisy. Concentrations of pleural fluid VEGF and endostatin were measured simultaneously using enzyme-linked immunosorbent assay (ELISA) and enzyme immunoassay, respectively. The sensitivity, specificity and accuracy were calculated.
RESULTS: PE levels of VEGF and endostatin were found to be significantly elevated in effusions with malignancy rather than in those of tuberculous origin (both P < 0.01). For VEGF, the sensitivity, specificity and accuracy in diagnosing malignant pleural effusions were respectively 71%, 61% and 66%, while for endostatin the values were respectively 69%, 83% and 76%. A combination of VEGF and endostatin can increase these to respectively 81%, 97% and 89%.
CONCLUSIONS: Elevated levels of VEGF and endostatin in pleural effusions may be helpful in diagnosing malignant pleural effusions, while a combination of VEGF and endostatin can increase the sensitivity, specificity and accuracy of differentiating malignant from tuberculous pleural effusions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275801

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  15 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: A meta-analysis.

Authors:  Yong-Chun Shen; Meng-Qi Liu; Chun Wan; Lei Chen; Tao Wang; Fu-Qiang Wen
Journal:  Exp Ther Med       Date:  2012-03-14       Impact factor: 2.447

3.  Lectin microarrays differentiate carcinoma cells from reactive mesothelial cells in pleural effusions.

Authors:  Yu-Qing Shi; Qun He; Yu-Jie Zhao; En-Hua Wang; Guang-Ping Wu
Journal:  Cytotechnology       Date:  2012-08-09       Impact factor: 2.058

4.  Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis.

Authors:  Amene Saghazadeh; Nima Rezaei
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

5.  Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions.

Authors:  Stacey D Finley; Aleksander S Popel
Journal:  J Natl Cancer Inst       Date:  2013-05-13       Impact factor: 13.506

Review 6.  Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.

Authors:  Amit Walia; Jessica F Yang; Yu-Hui Huang; Mark I Rosenblatt; Jin-Hong Chang; Dimitri T Azar
Journal:  Biochim Biophys Acta       Date:  2015-09-12

7.  Local ischemia and increased expression of vascular endothelial growth factor following ocular dissemination of Mycobacterium tuberculosis.

Authors:  Seema M Thayil; Thomas A Albini; Hossein Nazari; Andrew A Moshfeghi; Jean-Marie A Parel; Narsing A Rao; Petros C Karakousis
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

8.  Transcription expression and clinical significance of dishevelled-3 mRNA and δ-catenin mRNA in pleural effusions from patients with lung cancer.

Authors:  Xiao-Yan Li; Shu-Li Liu; Na Cha; Yu-Jie Zhao; Shao-Cheng Wang; Wei-Nan Li; En-Hua Wang; Guang-Ping Wu
Journal:  Clin Dev Immunol       Date:  2012-02-23

9.  Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review.

Authors:  Dawei Chen; Yan Zhang; Fang Shi; Minghuan Li; Hui Zhu; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2015-10-01       Impact factor: 4.147

10.  Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients.

Authors:  Dawei Chen; Yan Zhang; Fang Shi; Hui Zhu; Minghuan Li; Judong Luo; Kaijun Chen; Li Kong; Jinming Yu
Journal:  Oncotarget       Date:  2016-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.